DexCom, Inc. (NASDAQ:DXCM)’s share price shot up NaN on Thursday . The stock traded as high as $50.30 and last traded at $0.00. 3,227,333 shares changed hands during trading, an increase of Infinity from the average session volume of 0 shares.

Several brokerages have weighed in on DXCM. Barclays PLC lowered their price target on shares of DexCom from $60.00 to $57.00 and set an “equal weight” rating on the stock in a report on Thursday. Northland Securities reissued a “hold” rating and issued a $50.00 target price on shares of DexCom in a report on Thursday. Morgan Stanley lowered their target price on shares of DexCom from $72.00 to $52.00 and set a “neutral” rating on the stock in a report on Friday. Piper Jaffray Companies reissued a “buy” rating and issued a $78.00 target price on shares of DexCom in a report on Wednesday, July 12th. Finally, Wedbush reissued an “outperform” rating and issued a $76.00 target price (down previously from $85.00) on shares of DexCom in a report on Thursday, September 28th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $70.69.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.07. DexCom had a negative net margin of 7.21% and a negative return on equity of 20.44%. The business had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. During the same quarter in the previous year, the business posted ($0.24) earnings per share. The business’s revenue was up 24.3% compared to the same quarter last year. analysts predict that DexCom, Inc. will post -0.74 EPS for the current year.

In other DexCom news, EVP Andrew K. Balo sold 3,244 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $71.18, for a total transaction of $230,907.92. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Richard Doubleday sold 1,635 shares of the business’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $75.26, for a total transaction of $123,050.10. Following the transaction, the executive vice president now owns 72,395 shares in the company, valued at approximately $5,448,447.70. The disclosure for this sale can be found here. Insiders have sold 23,208 shares of company stock worth $1,597,567 in the last quarter. Company insiders own 1.70% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of DXCM. Janus Henderson Group PLC boosted its stake in shares of DexCom by 101,699.8% during the second quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock valued at $499,522,000 after purchasing an additional 6,822,023 shares during the period. Winslow Capital Management LLC purchased a new stake in shares of DexCom during the second quarter valued at $117,451,000. FMR LLC boosted its stake in shares of DexCom by 9.9% during the second quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock valued at $791,799,000 after purchasing an additional 978,898 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of DexCom by 27.3% during the second quarter. Bank of New York Mellon Corp now owns 3,242,928 shares of the medical device company’s stock valued at $237,221,000 after purchasing an additional 696,199 shares during the period. Finally, Fred Alger Management Inc. boosted its stake in shares of DexCom by 52.6% during the second quarter. Fred Alger Management Inc. now owns 2,018,116 shares of the medical device company’s stock valued at $147,625,000 after purchasing an additional 695,484 shares during the period.

ILLEGAL ACTIVITY WARNING: This piece was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/dexcom-inc-dxcm-shares-up-nan/1676551.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.